Evidence map›Paper›PMID 30911812›Full record

ArticleWorld journal of urology2019

Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.

Guoxian Zhang, Daniel Steinbach, Marc-Oliver Grimm, Marcus Horstmann

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Prediction for recurrent non-muscle invasive bladder cancer.Cancer biomarkers : section A of Disease markers · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guoxian ZhangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. xianguozh@hotmail.com.ORCID http://orcid.org/0000-0002-3479-3470
Daniel SteinbachDepartment of Urology, Friedrich Schiller University, Jena, Germany.
Marc-Oliver GrimmDepartment of Urology, Friedrich Schiller University, Jena, Germany.
Marcus HorstmannDepartment of Urology, Friedrich Schiller University, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRoutine second transurethral resection (TUR) for non-muscle-invasive bladder cancer (NMIBC) is common practice in Germany. Applicability of European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) models in NMIBC patients is still controversial. Aim of the study was to assess the performance of EORTC and CUETO predictive models in NMIBC patients treated with second TUR.

methods479 NMIBC patients with routine second TUR were analyzed retrospectively between 2003 and 2011, and investigated with clinical and pathological variables in regard to tumor recurrence and progression. Furthermore, recurrencefree survival (RFS) and progression-free survival (PFS) were evaluated according to EORTC and CUETO, and the discrimination of the models assessed.

resultsWith a median follow-up of 60 months, prior recurrence rate, grade, and second TUR pathology were independent prognostic factors for the risk of disease recurrence and progression. The concordance index of the EORTC and the CUETO model was 0.563 and 0.516 for recurrence and 0.681 and 0.702 for progression, respectively. The positive pathology after second TUR was significantly associated with risk of disease recurrence and progression. EORTC and CUETO risk models estimated progression better than recurrence, especially with higherscore groups.

conclusionsImproved predictive tools should be developed for optimal treatment selection.

Indexed as

Models, StatisticalRisk AssessmentAgedAged, 80 and overDisease ProgressionEuropeFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalOrganizationsPrognosisReoperationRetrospective StudiesBladder cancerCUETOEORTCProgressionRecurrenceSecond TUR

Identifiers

PMID30911812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.